Schizophrenia Bulletin Advance Access originally published online on September 8, 2005
Schizophrenia Bulletin 2005 31(4):870-874; doi:10.1093/schbul/sbi047
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Distinguishing Separable Domains of Cognition in Human and Animal Studies: What Separations Are Optimal for Targeting Interventions? A Summary of Recommendations From Breakout Group 2 at the Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches Conference
Departments of Psychiatry and Psychology, University of California, Los Angeles, 300 UCLA Medical Plaza, Room 2251, Los Angeles, CA 90095-6968
Cambridge University
College of Pharmacy, University of Minnesota, Duluth
To whom correspondence should be addressed; phone: 310-825-0036, fax: 310-206-3651, e-mail: keithn{at}ucla.edu.
At the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) New Approaches Conference, a discussion group focused on directions for future research that are critical to enhancing our understanding of the distinctions among key cognitive domains that have relevance for the development of cognition-enhancing interventions. One set of recommendations emphasizes the need for examining and optimizing the psychometric properties of relevant measurement paradigms from cognitive psychology and cognitive neuroscience. This step is critical to translating many notable advances in these basic fields into measures that would be appropriate for clinical trials. A second set of recommendations focuses on key directions for the development and application of animal models of cognitive processes that would greatly aid the discovery and preclinical testing of potential cognition-enhancing agents. As part of this process, the group noted several existing animal paradigms that have particular promise as measures in the key cognitive domains in schizophrenia identified by the MATRICS Neurocognition Committee.
Keywords: neurocognition / clinical trials / behavioral neuroscience
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. M. Barch, C. S. Carter, and the CNTRICS Executive Committee Measurement Issues in the Use of Cognitive Neuroscience Tasks in Drug Development for Impaired Cognition in Schizophrenia: A Report of the Second Consensus Building Conference of the CNTRICS Initiative Schizophr Bull, July 1, 2008; 34(4): 613 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Matza, R. Buchanan, S. Purdon, J. Brewster-Jordan, Y. Zhao, and D. A. Revicki Measuring Changes in Functional Status Among Patients With Schizophrenia: The Link With Cognitive Impairment Schizophr Bull, October 1, 2006; 32(4): 666 - 678. [Abstract] [Full Text] [PDF]
|
|